加载中
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
收盘时
US$4.66
−US$0.15 · -3.12%
盘后
US$4.60
−US$0.06 · -1.29%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
日内区间
当前US$4.66
52周区间
当前US$4.66
盘中时间采用ET。市场数据可能有所延迟。
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
日内区间
当前US$4.66
52周区间
当前US$4.66
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.34亿 USD | 1.4亿 USD | 8907.7万 USD | 4900.5万 USD | 2259.3万 USD |
| 销货成本 | 3146.9万 USD | 4098.4万 USD | 3531.2万 USD | 2767.7万 USD | 1807.6万 USD |
| 毛利 | 1.03亿 USD | 9894.3万 USD | 5376.5万 USD | 2132.8万 USD | 451.7万 USD |
| 研究与开发 | 3854.9万 USD | 3436.7万 USD | 2905.1万 USD | 2598.1万 USD | 2449.9万 USD |
| 销售、一般及管理费用 | 1.13亿 USD | 1.01亿 USD | 7479.9万 USD | 5866.5万 USD | 3280.5万 USD |
| 营业费用 | 1.51亿 USD | 1.36亿 USD | 1.04亿 USD | 8464.6万 USD | 5730.4万 USD |
| 利息收入 | 250.8万 USD | 947.4万 USD | 657.4万 USD | 151.7万 USD | 5.4万 USD |
| 利息支出 | 4万 USD | 2.1万 USD | 330.8万 USD | 494.6万 USD | 368.2万 USD |
| 折旧和摊销 | 326.6万 USD | 362.4万 USD | 424.3万 USD | 402.2万 USD | 398.8万 USD |
| 营业利润 | −4819万 USD | −3685.8万 USD | −5008.5万 USD | −6331.8万 USD | −5278.7万 USD |
| 净利润 | −3894.3万 USD | −2745.5万 USD | −4860.8万 USD | −6675.6万 USD | −4868.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$7.31
上涨空间 56.87%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI899.5万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM501.37万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF300.01万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO168.24万0.01%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA95.5万0.00%218.24亿 USD0.03%US$32.66-0.40%
Vanguard Health Care ETFVHT87.57万0.00%220亿 USD0.09%US$320.67+0.52%
iShares Micro-Cap ETFIWC60.11万0.05%13.17亿 USD0.60%US$181.66-0.73%
Invesco RAFI US 1500 Small-Mid ETFPRFZ31.01万0.01%26.7亿 USD0.36%US$52.92-0.45%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
